Conflict of Interest Disclosures: Dr Valtis reported receiving grants from National Cancer Institute (NCI) during the conduct of the study and personal fees from EastRx outside the submitted work. Dr Yisraeli Salman reported receiving personal fees from SOBI Inc MJH Life Sciences outside the submitted work. Ms Brooklyn reported receiving personal fees from Bristol Myers Squibb (BMS) and Iovance outside the submitted work. Dr Shah reported receiving research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, GPCR, and Recordati and serving on the Data and Safety Monitoring Board for ArcellX. Dr Scordo reported receiving personal fees from Kite and Miltenyi Biotec during the conduct of the study; research funding to institution and personal fees from Omeros Corporation and i3Health; research funding to institution and grants from BMS, Sanofi, and Amgen Inc; and personal fees from McKinsey & Company, Angiocrine Bioscience Inc, Medscape, CancerNetwork, Intellisphere LLC, Curio Science LLC, and IDEOlogy outside the submitted work. Dr Boardman reported receiving personal fees from BMS outside the submitted work. Dr Shouval reported receiving personal fees from Incyte and Sanofi outside the submitted work. Dr Geyer reported receiving grants from NCI and research support from Actinium Pharmaceuticals Inc during the conduct of the study and personal fees from Tigen Pharma, Takeda, Jazz, and Sanofi outside the submitted work. Dr Mailankody reported receiving research funding to institution from Takeda Oncology, BMS, Janssen, Fate Therapeutics, Allogene Therapeutics, and Caribou Therapeutics and personal fees from Legend Biotech, Optum Oncology, BMS, Janssen, Astra Zeneca, ArcellX, and AbbVie during the conduct of the study. Dr Palomba reported receiving personal fees from Synthekine, BMS, Novartis, and Kite outside the submitted work. Dr Usmani reported receiving grants from Janssen, Sanofi, GSK, AstraZeneca, Gilead, BMS/Celgene, and Abbvie and personal fees from Oricell Therapeutics, Gracell Therapeutics, Pfizer, and Regeneron outside the submitted work. Dr Salles reported receiving grants from Abbvie, Genentech/Roche, and Ipsen and personal fees from Beigene, BMS, Foresight, Genmab, Janssen, Kite/Gilead, Lilly, Merck, Novartis, Pfizer, SERB Pharmaceuticals, Ellipses, and Incyte outside the submitted work. Dr Giralt reported receiving personal fees and grants from Kite, BMS, and Johnson & Johnson during the conduct of the study and personal fees and grants from Amgen and Actinuum, personal fees from Omeros and Jazz, and grants from Sanofi outside the submitted work. Dr Perales reported receiving clinical trial support from Allogene, Incyte, Kite/Gilead, Nektar Therapeutics, Novartis, VectivBio AG, and Miltenyi Biotec and personal fees from Adicet, Karyopharm, Caribou Biosciences, Celgene, BMS, Equilium, Exevir, ImmPACT Bio, Incyte, Kite/Gilead, Merck, Nektar Therapeutics, Novartis, Vor Biopharma, Sanofi, and Takeda outside the submitted work. Dr Park reported receiving personal fees from Iovance, Jazz Pharmaceuticals, Takeda, Caribou Biosciences, Synthekine, Novartis, BMS, Kite Pharma, Autolous, Allogene, Curocel, and Artiva outside the submitted work. No other disclosures were reported.